You are here

Soliris

Alexion shares slide on Amgen patent challenge to top-seller

Alexion shares slide on Amgen patent challenge to top-seller

Biopharma Dive

inter partes review

Flag link:

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?

Fierce Pharma

Flag link:

Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Pharmaforum

Flag link:

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication

Endpoints

autoimmune disease

Flag link:

FDA Action Alert: Regeneron, Sanofi, Celgene

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

Flag link:

3 Drug Stocks That Could Win From Key FDA Approvals in June

3 Drug Stocks That Could Win From Key FDA Approvals in June

Motley Fool

Amag Pharmaceuticals

Flag link:

Go or no go? Merck, Regeneron and Alexion await US expansion

Go or no go? Merck, Regeneron and Alexion await US expansion

EP Vantage

Dova Pharmaceuticals

Flag link:

Alexion gets off to the races with key Ultomiris, Soliris launches

Alexion gets off to the races with key Ultomiris, Soliris launches

Fierce Pharma

Flag link:

Alexion aims for fourth rare disease use for blockbuster Soliris

Alexion aims for fourth rare disease use for blockbuster Soliris

Pharmaforum

Alexion Pharmaceuticals

neuromyelitis optica spectrum disorder

Flag link:

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Stat

Alexion Pharmaceuticals

Flag link:

Ra Pharma files $100M round as Soliris rival clears phase 2 trial

Ra Pharma files $100M round as Soliris rival clears phase 2 trial

Fierce Biotech

clinical trials

myasthenia gravis

Flag link:

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M

Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M

Endpoints

clinical trials

Flag link:

How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass

How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass

Biopharma Dive

priority review

Flag link:

Alexion's follow-on stacks up to Soliris

Alexion's follow-on stacks up to Soliris

Biopharma Dive

paroxysmal nocturnal hemoglobinuria

Flag link:

Alexion turns focus to rebuilding pipeline amid restructuring

Alexion turns focus to rebuilding pipeline amid restructuring

Biopharma Dive

Flag link:

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

Endpoints

Flag link:

Alexion cutting 600 jobs and moving headquarters in major shakeup

Alexion cutting 600 jobs and moving headquarters in major shakeup

Stat

Flag link:

Alexion bolsters Soliris patent defense

Alexion bolsters Soliris patent defense

BioPharma Dive

Flag link:

Pages